Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Meth

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Spectrum International and its two top execs plead guilty to distributing pseudoephedrine tablets "knowing or having reasonable cause to believe that [they] would be used to manufacture methamphetamine," U.S. Attorney in Los Angeles announces Oct. 23. Spectrum president Charles Eisele, along with his brother and VP Richard Eisele, distributed roughly 1.1 bil. Ephedrine Release and Ephrin Release tablets between June 1996 and January 1998 to firms that sent pills to meth labs. Billings, Mont.-based company will pay $2 mil. in forfeiture and fines. Defendants will be sentenced Feb. 7 by Los Angeles federal Judge Howard Matz and face a maximum sentence of four years in prison and a $250,000 fine

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

Idorsia’s Novel Hypertension Pill Among Eight New Drugs To Win EMA Nod

See All
UsernamePublicRestriction

Register

PS093210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By